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We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse
cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients’ serum before
revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a
cohort of healthy subjects (median, IQ: 15.9, 9.0–264 pg/mL versus 419, 212–758 pg/mL; 𝑃 < 0.001) at baseline. VEGF increased to
1-month (median, IQ: 276, 167–498 pg/mL; 𝑃 < 0.001) and remained steady to 1-year (median, IQ: 320, 173–497 pg/mL; 𝑃 < 0.001)
approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution
after intervention (𝑃 < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up.
Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.
1. Introduction
Vascular endothelial growth factor (VEGF) is an endothelial
cell-specific mitogen. There are multiple direct and positive
actions of VEGF in the endothelial function of adult resis-
tance vessels. Some of the effects of VEGF stimulation on
endothelial cells demonstrated in vitro and in animal models
include cell motility and proliferation [1, 2], upregulation of
endothelial nitric oxide synthase (NOS) [3], production of
prostaglandins [4], modulation of apoptosis [5], permeability
[6], protection mechanisms to manage increased shear stress
[2, 7], and leukocyte adhesion [8], among others. VEGF
signalling is required to stabilize the vasculature and to
protect the endothelium by providing survival signals. The
most important molecule regulating vascular development
and angiogenesis in adults is the ligand VEGF-A (or VEGF)
form, which exerts its actions via the VEGF receptor 1
(VEGFR-1) and VEGF receptor 2 (VEGFR-2).
It is currently accepted that VEGF plays an essential role
in the normal vasculature and in the diseased vessels and
that the mechanisms of action where VEGF intervenes are
essentially different of those occurring in tumour angiogene-
sis [6, 9, 10].
VEGF has long been associated with coronary artery dis-
ease (CAD). The observation of VEGF release from platelets
during clotting [11] together with the detection of increased
VEGF mRNA expression in specimens of myocardium with
evolving infarction but not in normal tissue [12] called
the attention for the possible association of the levels of
this protein with CAD phenotypes. However, the reported
increases of VEGF expression in the myocardium following
acute events were not unequivocally detected in the serum of
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patients; neither have the changes of VEGF levels in different
clinical presentations reached a consensus [13–16].
The clinical correlations of systemic levels of VEGF in
CAD and especially after revascularization intervention are
largely unknown. Published data is scarce and only describes
short-term changes of VEGF circulating levels after percuta-
neous coronary intervention (PCI) [17–19] or bypass surgery
[13, 20] in small number of patients. Recently, emerging
evidence suggests VEGF may have a protective net effect in
the vasculature, giving rise to well-developed coronary col-
lateral arteries in patients with CAD after revascularization
intervention [21]. Therefore high VEGF levels would confer
a better prognosis in CAD patients undergoing intravascular
intervention as its actions may contribute to ameliorate the
damaged endothelium and promote rapid recovery. The aim
of this study was to investigate this hypothesis in CAD
patients submitted to PCI by repeatedlymeasuringVEGF in a
long-term basis, from baseline to 1-year and by examining the
possible association of VEGF levels with futuremajor adverse
cardiac events (MACE) in a 5-year follow-up.
2. Methods
2.1. Study Population. This study included patients with coro-
nary artery disease presented to the Cardiology Service of
the SantaMartaHospital (CHLC, Lisbon, Portugal) requiring
invasive evaluation by PCI.
Ninety-four patients, men and women aged between 42
and 82, undergoing PCI for acute coronary syndromes (ACS)
(𝑁 = 58)—ST-elevation and non-ST-elevation myocardial
infarction and unstable angina—or for non-ACS (𝑁 =
36)—chronic stable angina—were prospectively eligible. ACS
patients were admitted to the hospital in the first 6 hours
after the onset of symptoms and enrolled in the study
shortly after. Approximately 90% of the patients had stent
placement (either drug eluting stent or bare metal stent
types). All patients received standard care therapy including
dual antiplatelet therapy after PCI.
Exclusion criteria were age above 85, myocardial infarc-
tion in the previous 5 years, peripheral artery disease or
carotid artery disease, malignance or infectious diseases,
chronic renal insufficiency, and concurrent inflammatory
disorders.
A control group was constituted to help interpreting
VEGF changes in patients from baseline to 1-year, as there
are no reference values for the Portuguese population. The
harmonization between controls and patients concerning
age, gender, and risk factors was taken into account. Forty-
four healthy volunteers were recruited at the preventive
cardiology outpatient’s clinic and enrolled in the study as
controls. These individuals had no history of CAD and
no signs or symptoms of coronary disease, based on ECG
with negative stress test and normal endothelial function
(ENDOPAT, peripheral arterial tonometry).
The CHLC Ethical Committee board approved the study
protocol and all patients signed informed consent.
2.2. Longitudinal Study. Patients were evaluated 3 times over
one-year: at admission and 1-month and 1-year after. At
hospital admission, blood was drawn before PCI and any
medication intake. At each evaluation point, core laboratory
analysis of blood samples was performed for conventional
tests and clinical chemistry, including N-terminal pro-brain
natriuretic peptide (NT-proBNP) and C-reactive protein
(CRP). All parameters were also measured in controls.
2.3. Follow-Up Evaluation and Study End Points. Patients
were followed up annually for a period up to 5 years
(24 ± 19 months) after the initial admission by clinic visits,
telephone interviews, and analysis of hospital databases and
clinical notes.The primary end points considered were death
(with cardiac or procedure-related origin), ischemic events,
hospital re-admission (for catheterization, PCI, or by-pass
surgery), and CAD-related cardiovascular aggravation. The
combination of primary end points rendered the secondary
end point of major adverse cardiac events (MACE).
2.4. Quantification of Vascular Endothelial Growth Factor.
Blood samples were processed within the hour after col-
lection. Peripheral blood was centrifuged at 2500 rpm for
10 minutes. Serum was collected and stored at −80∘C until
analysis, for a period not exceeding 6 months. Samples were
thawed only once. Serum concentrations of VEGF were
measured by specific ELISA assays (designed to measure
human VEGF-165 or VEGF-A) using the Quantikine Human
VEGF kit (R&D Systems) according to the manufacturer’s
protocol. Each sample was measured in duplicate; intra-assay
variation among the duplicates for all samples was <10%.The
limit of detection of the assay was 9 pg/mL.
2.5. Statistical Analysis. Data were summarized and repre-
sented as median and interquartiles (IQ) 25% and 75% (Q25–
Q75) for continuous variables and as proportions for categor-
ical variables. The detection limit (DL) value of 9 pg/mL was
assigned to samples with VEGF levels below DL. Categorical
variables were analyzed using a 2 × 2 table and 𝜒2 test.
Continuous variables were analysed using a Mann-Whitney
test. Data consisted of repeated measurements on the same
subject taken over time. To characterize the changes over time
within-subjects, free of any between-subject variability and
the variation in the time trends between-subjects, statistical
linear mixed-effects models (LME) were used. The rela-
tionship between VEGF concentration in serum (response
variable) through time (basic model) and the covariates
observed or measured along with the response (as additional
random effects), such as biochemical and clinical variables
and medication, was evaluated. Examination of data indi-
cated that it would be advantageous to take the square root
transformation of VEGF, as the distribution for both groups
of subjects becomes more symmetric and linearizes the rela-
tionship between VEGF and time.Themodel parameters and
coefficients were estimated on the basis of the corresponding
restrictedmaximum likelihood value (considered statistically
significant for 𝑃 < 0.05). Receiver operating characteris-
tics (ROC) curve analyses over the dynamic range of the
exposure variable were used to identify the threshold level
granting highest predictive value for risk-stratifying patients
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Table 1: Patients demographic, clinical, and biochemical characteri-
zation. Results are presented inmedian (Q25–Q75) unless otherwise
specified.




Male sex (𝑛, %) 28, 64 66, 70
Age (y) 58 (52–67) 62 (56–71)
Weight (kg) 72 (65–80) 76 (65–80)
Height (m) 1.6 (1.6–1.7) 1.6 (1.6–1.7)
Risk factors/comorbiditiesa
Smoking (𝑛, %) 4, 9 18, 20
Obesity (𝑛, %) 25, 61 67, 74
Hypercholesterolemia (𝑛, %) 22, 50 61, 66
Arterial hypertension (𝑛, %) 17, 39 74, 80∗
Diabetes mellitus (𝑛, %) 0 39, 42∗
Previous medication
Aspirin (𝑛, %) 4, 9 58, 64∗
ACE inhibitors (𝑛, %) 9, 21 44, 49∗
Antiplatelets (𝑛, %) 0, 0 48, 52∗
𝛽-Blockers (𝑛, %) 3, 7 41, 45∗
Statins (𝑛, %) 10, 23 62, 68∗
Diagnostic markers
CRP (mg/L) 1.6 (1–3.7) 4.3 (3.0–13.9)∗
NT-ProBNP (pg/mL) 33 (11–64) 148 (53–780)∗
VEGF (pg/mL) 419 (212–758) 15.9 (9.0–264)∗
𝑎
Diabetes: fasting plasma glucose concentration ≥7.0mmol/L or 2 h plasma
glucose ≥11.1mmol/L or confirmed as clinically known and treated diabetes
mellitus; hypertension: systolic blood pressure ≥140mmHg or diastolic
blood pressure ≥90mmHg or use of antihypertensive therapy; dyslipidemia:
total serum cholesterol≥190mg/dL or serum triglycerides≥180mg/dL or use
of lipid-lowering medication; smoking: inhaled use of cigarettes, cigars, or
pipes in any quantity, in the year previous to admission.
∗Significant differences to controls (𝑃 ≤ 0.01).
with CAD. A Cox proportional-hazards regression analysis
was performed for the primary and combined end points.
Analyses were censored at 36 months. The calculations were
performed using SPSS (version 21.0) and R (V.3.0.2).
3. Results
3.1. Demographics and Clinical Information at Baseline.
Patients showed higher prevalence of arterial hypertension
and diabetes than controls (see Table 1). The diagnostic
markers of inflammation, CRP, cardiac dysfunction, and NT-
proBNP were altered in patients. The circulating levels of
both markers exceeded reference values and consequently
differed from the levels measured in control individuals
(Table 1). Over 78% of the enrolled patients took at least one
prescription drug, whereas only 27% of the controls were on
any medication.
3.2. Patient’s Angiographic Information at Baseline. Angio-
graphic and procedural findings were similar in ACS and
non-ACS patients (Table 2). The presence of multivessel
disease, the number of lesions in the left anterior descend-
ing artery, the length of lesions, and their morphological
characteristics were identical in ACS and non-ACS patient’s
groups. ACS patients showed higher disease complexity with
higher SYNTAX score values (range of 56), whereas non-ACS
patients showed consistently lower scores (range value of 39;
𝑃 < 0.001). Stents, DES or BMS type, were positioned in 73
patients.
3.3. VEGF Changes over 1-Year. The VEGF concentration in
serum at baseline was decreased in CAD patients relative to
controls (Table 1). No significant differences between ACS
and non-ACS patients were observed (median, IQ: ACS =
16.6, 9.0–263 pg/mL; non-ACS = 18.2, 9.0–295 pg/mL; 𝑃 >
0.05). Remarkably, 50% of ACS patients and 43% of non-
ACS patients had VEGF concentration bellow the detec-
tion limit (9 pg/mL) at baseline. None of the controls had
VEGF concentration below detection limit. No effect of any
medication or risk factors on VEGF levels was observed,
either considering all patients or ACS and non-ACS groups
of patients. Also, there is no correlation between VEGF levels
and cardiac or inflammatory markers, that is, NT-proBNP
and CRP.Therefore, the VEGF concentrations in serum were
significantly diminished in CAD patients, but their levels did
not differ as a function of clinical presentation.
Patients were reevaluated 1-month and 1-year after inter-
vention. The VEGF concentration showed a positive evo-
lution through time in 84% of patients. The longitudinal
changes of VEGF concentrations in the serum of patients
significantly increased to 1-month and remained relatively
steady to 1-year approaching the VEGF levels of controls
(Figure 1). The interaction of type of stent positioned in the
model of VEGF changes over time significantly influenced
the average changes of VEGF from baseline to 1-year. The
number of drug eluting stents (DES) positioned was corre-
latedwith a decrease in the average changes of VEGF to 1-year
(𝑃 = 0.05). Counteracting this trend, patients carrying bare
metal stents (BMS) showed a more steep average change in
VEGF increases to 1-year (𝑃 = 0.04).
The model of VEGF changes over time was not signif-
icantly altered by the interaction of patient’s clinical pre-
sentation (ACS and non-ACS), risk factors, angiographic
characteristics, and specific biochemical indicators, such as
CRP and NT-proBNP. Similar intercepts and slopes were
produced indicating the lack of influence of the predictor
variables on VEGF levels at the baseline and in the evolution.
3.4. Follow-Up Evaluation. The VEGF levels at admission
were related to a 5-year follow-up analysis considering read-
mission (single end point) andMACE (composite end point).
Table 3 summarizes data for patients considering end points
and the respective median time of event. Nineteen patients
(28%) suffered MACE, with a median time of event of 10
months (IQ: 3–16). Lower VEGF concentrations at admission
were significantly associated with patients with MACE com-
pared to patients with higher VEGF: 9.0 versus 88.6 pg/mL;
𝑃 = 0.028. Consistently with these results the ROC curve
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Table 2: Angiographic and procedural data expressed as within-group percentage of the total number of patients (%) unless otherwise
specified.
All patients ACS Non-ACS
Multivessel disease (𝑛, %) 29, 31 19, 33 10, 29
Sintax Score¥ 9.5 (3.5–17.5) 15.5 (9.5–22.8) 4.0 (0–8.8)∗
Intervened vessel (𝑛, %)
Left anterior descending artery 46, 51 29, 52 17, 50
Right coronary artery 28, 31 21, 38 7, 21
Left circumflex artery 11, 12 6, 11 5, 15
Left main artery 4, 4 0, 0 4, 12
Number of intervened lesions (𝑛, %)
1 52, 59 38, 68 14, 44
>1 20, 23 13, 23 7, 22
Lesion length (mm)¥ 22 (16–30) 22 (16–35) 16 (13–26)
Long lesion (>15mm) (𝑛, %) 50, 77 36, 78 14, 74
Type B/C lesion (𝑛, %) 55, 86 41, 89 14, 78
Eccentric lesion (𝑛, %) 44, 75 29, 76 15, 71
Calcified lesion (𝑛, %) 17, 21 13, 25 4, 13
Thrombotic lesion (𝑛, %) 13, 16 12, 23 1, 3∗
Stent type (𝑛, %)
DES 50, 63 34, 65 16, 57
BMS 15, 19 11, 22 4, 14
¥
Results expressed as median and interquartile (Q25–Q75).
∗Significant difference to ACS (𝑃 < 0.05).
Table 3: Patient’s follow-up evaluation, according to study end-
points. Time for event expressed as median (Q25–Q75).
Study end point Positive cases(𝑛, %)
Time for event
(months)
Death 6, 9 3 (2–34)
Readmission 12, 18 13 (5–19)
Ischemic episode 6, 9 6 (1–15)
Cardiovascular aggravation 7, 10 ∗
Composite end point MACE 19, 28 10 (3–16)
∗
Based on annual clinical follow-up for 5-years.
analysis indicated a cut-off level of 40.8 pg/mL formaximized
predictive value for MACE (area under the curve of 0.664;
79% sensitivity; 56% specificity; 𝑃 = 0.037). CAD group
was dichotomized according to the calculated threshold level.
Patients in the lower class of VEGF concentration showed
increased risk for MACE, as represented in Figure 2 (Hazard
Plot). The hazard ratio determined by a Cox regression was
4.4 (95% CI, 1.4 to 13.3; 𝑃 = 0.009). Patients in the lower
class of VEGF also showed increased risk for the primary end
point of readmission (hazard ratio of 5.2; 95% CI, 1.1 to 24.1;
𝑃 = 0.033).
4. Discussion
This study shows that the VEGF concentrations in the
serum of CAD patients requiring PCI, either with acute or





















Figure 1: VEGF concentration in controls and in patients at
admission, 1-month and 1-year after.
individuals without CADor any history of CAD. VEGF levels
increased over 1-year although 1-month after intervention the


























Figure 2: Cumulative hazard for MACE according to VEGF levels
(<40.8 and ≥40.8 pg/mL).
concentration <40.8 pg/mL at admission was related to
increased risk of MACE in a 5-year follow-up analysis.
A literature review of the clinical studies involving CAD
patients showed that reported increases of VEGF in the
circulation could be either beneficial or detrimental. VEGF
changes in serum or plasma of patients with CAD relative
to individuals without the disease varied from increased
levels [15, 17] to decreased levels [16] or no changes [13, 22].
High VEGF levels were associated with patients who died of
CAD [23] and with worst prognostic of ACS patients [14].
Opposite to these studies, decreased VEGF were associated
with myocardial infarction history and CAD severity [24].
Our data are in line with the previous studies that have
shown that VEGF increased through time after PCI. These
studies have also evidenced the importance of the time gap of
patient’s evaluation on VEGF assessment. To our knowledge
few studies have examined VEGF levels in CAD patients
longitudinally after PCI [17–19]. None of previous studies
reported on changes over 1-year period after stent apposition.
However, consistent VEGF increases were reported on ACS
and non-ACS patients after PCI as found in our study. In
a small group of patients (𝑛 = 7) with acute myocardial
infarction the VEGF increases were only significant 7 days
after the intervention stabilizing to 180 days [17]. Banerjee
et al. studied the variations of VEGF in a short period of
12 h after PCI and observed a faster VEGF increase in ACS
patients when compared to non-ACS patients [18].
In our study, independently of clinical presentation, risk
factors, and angiographic characteristics, there was a positive
increasing trend inVEGF levels frombaseline to 1-year, which
was steeper to 1-month. However, previousmedication intake
influenced the rate of VEGF evolution to 1-month but not
the values at the baseline. Also, drug eluting stent apposition
produced a negative effect in the VEGF average changes
after PCI evidencing a delay to reach control values to 1-
year, which was not observed for bare metal stents. Decreases
in VEGF levels were also reported on non-ACS patients
treated either with statins [22] or with sirolimus eluting
stent 1-month after apposition, but not in patients with bare
metal stents [19]. By treating stenosis the ischemic trigger
of angiogenesis is reduced [25] and this might be explained
by the increase of VEGF levels [26]. This issue is relevant
considering endothelial dysfunction after drug eluting stent
apposition when compared with bare metal stent [27, 28].
Many observations suggest that endothelial cell dysfunc-
tion is crucially involved in the pathogenesis of atherosclero-
sis. Therefore, the consequences of low concentration levels
of soluble VEGF in CAD patients must be discussed in the
light of endothelial dysfunction. Moreover recent studies
suggest that the mechanisms of action of VEGF in the
normal vasculature and in the diseased vessels are different.
At the ligand level, VEGF activities are controlled not only
by its own level of expression, but also by the expression
of various proteins that can bind and sequester it [29–32].
There are several evidences that VEGFR-1, existing either as a
membrane bound form or as a soluble form [33], may act as a
VEGF trap due to its poor kinase activity and high-affinity
to VEGF, moderating the amount of free VEGF available
to activate VEGFR-2 [34], the key receptor mediating most
of cellular effects of VEGF in the endothelium [1, 2]. In
fact, the overexpression of soluble VEGFR-1 was found to
suppress phosphorylation of VEGFR-2 at specific sites in
vitro and in placenta of preeclamptic women [34]. Also, Di
Marco et al. demonstrated that the excess of VEGFR-1 in
plasma of patients with chronic renal failure was associated
with endothelial dysfunction and with cardiovascular risk
[35]. These findings suggest that soluble VEGFR-1 would
be more available in endothelial dysfunction conditions to
sequester circulating VEGF. This hypothesis is in line with
our findings of decreased VEGF levels in CAD patients at the
baseline and of low VEGF concentrations (<40.8 pg/mL) in
association with the increased risk of rehospitalization and
combined adverse cardiac events in a 5-year follow-up. It
should also be taken into account that the binding of VEGF
to soluble VEGFR-1 in the circulation may mask the VEGF
epitopes, hampering antigen detection by ELISA [36], which
was the method used in this study and in the majority of
published clinical studies. This would support the VEGF
levels below detection limit in almost 50% of the ACS and
non-ACS patients at the baseline, observed in our study. As
normal endothelial function is restored the VEGF levels in
patients approximated control values, which possibly reflect
the physiological balance between free and bound VEGF in
the circulation.
However, it would be crucial to study the interplay of
VEGF soluble forms in the blood circulation of CADpatients.
This will certainly improve the knowledge about the balance
between VEGF ligands and receptors in health and disease
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and the understanding of their implications in the temporal
control of signalling outputs.
5. Conclusion
In conclusion this study showed that VEGF levels in CAD
patients progressively increase after revascularization during
1-year reaching the levels observed in controls. In addition,
the increase in VEGF levels was associated with diminished
occurrence of major adverse cardiac events for 5 years.
Despite the limited number of patients evaluated in the study,
results reflect a positive role of VEGF in endothelial function
improvement after PCI.
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